Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2022
Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims DatabaseTakashi Kadowaki, Issei Komuro, Naru Morita, et al.Anesthesia and Analgesia|September 30, 2005
Sevoflurane pretreatment inhibits endotoxin-induced shock in ratsYoko Kidani, Takumi Taniguchi, Hiroko Kanakura, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2014
Gene expression in the Gitr locus is regulated by NF-κB and Foxp3 through an enhancerYukiko Tone, Yoko Kidani, Chihiro Ogawa, et al.Transplantation|November 8, 2016
Bruton Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion ModelTiziana Palumbo, Kojiro Nakamura, Charles Lassman, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 28, 2021
Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVERMitsuyoshi Takahara, Tomoya Mita, Naoto Katakami, et al.Cell Host & Microbe|May 22, 2012
Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infectionElizabeth B Wilson, Yoko Kidani, Heidi Elsaesser, et al.The Journal of Clinical Endocrinology and Metabolism|July 20, 2022
Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line TreatmentTomoya Mita, Naoto Katakami, Mitsuyoshi Takahara, et al.Advanced Materials (Deerfield Beach, Fla.)|January 10, 2018
Cytokine Secreting Microparticles Engineer the Fate and the Effector Functions of T-CellsFatemeh S Majedi, Mohammad Mahdi Hasani-Sadrabadi, Yoko Kidani, et al.Journal of Thrombosis and Thrombolysis|August 22, 2019
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settingsTakanori Ikeda, Satoshi Ogawa, Takanari Kitazono, et al.Cerebrovascular Diseases (Basel, Switzerland)|October 3, 2019
Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic AttackKazuo Minematsu, Takanori Ikeda, Satoshi Ogawa, et al.Pageof 3